Tianjin Ruiwang New Material Technology Co Safety Rating & Test Results

As of 25 Jul 2026, Finnrick has published 156 independent lab tests of 8 peptides from Tianjin Ruiwang New Material Technology Co: 106 passed, 49 failed, and 1 was not classifiable (incomplete data) under the default public standard, Purity Focus (HPLC purity at least 99.5%, fill within ±35% of the label claim). The latest test is dated 1 Jul 2026.

Finnrick ratings are recency-weighted pass percentages: newer tests count more, and vendors with thin test histories are pulled toward the peer baseline for that peptide, so a single result cannot look too certain. Samples are analyzed by independent partner laboratories and the results are published by Finnrick Analytics, which does not sell peptides and does not accept payment to alter ratings. Corrections to published data are recorded at finnrick.com/corrections.

Purchased from Tianjin Ruiwang New Material Technology Co? Submit a sample to Finnrick for free independent lab testing — results are published publicly.

Are you Tianjin Ruiwang New Material Technology Co? Finnrick offers professional testing services and a public launch program for peptide vendors.

Interactive charts, prices, and test history for this page load with JavaScript; the facts above are from Finnrick's published test database.

Tianjin Ruiwang New Material Technology Co peptides tested by Finnrick, rated under the default public methodology.
PeptideFinnrick ratingLab testsLatest test
BPC-15745%131 Jul 2026
GHK-Cu94%198 Jun 2026
Ipamorelin65%528 Apr 2026
Retatrutide79%6017 Jun 2026
Semaglutide59%528 Apr 2026
TB-50027%76 May 2026
Tesamorelin43%1512 Jun 2026
Tirzepatide76%3228 Apr 2026